In this episode of Denatured, BioSpace's Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the ...
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
As market values increase for computational biology and data science, biopharma companies are looking to hire R&D ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...
As a major biotech hub, including the hotbed regions of Biotech Bay and Biotech Beach, California always has companies ...
LONDON, UK / ACCESSWIRE / December 30, 2024 / Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)(LSE:HEMO) is pleased to announce the opening of the first clinical site for ...
The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...
MANHASSET, N.Y.--(BUSINESS WIRE)--For years, The Feinstein Institutes for Medical Research has been calling attention to the historical lack of diversity and inclusion in medical and scientific ...
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback